Literature DB >> 16829347

From cheese to pharma: a designer probiotic for IBD.

Charles O Elson.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16829347      PMCID： PMC1679867          DOI： 10.1016/j.cgh.2006.05.034

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  13 in total

1.  Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination.

Authors:  A S Neish; A T Gewirtz; H Zeng; A N Young; M E Hobert; V Karmali; A S Rao; J L Madara
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

Review 2.  Probiotics and immune regulation of inflammatory bowel diseases.

Authors:  Yingzi Cong; Astrid Konrad; Nuzhat Iqbal; Charles O Elson
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2003-06

Review 3.  Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota.

Authors:  Charles O Elson; Yingzi Cong; Vance J McCracken; Reed A Dimmitt; Robin G Lorenz; Casey T Weaver
Journal:  Immunol Rev       Date:  2005-08       Impact factor: 12.988

4.  Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

Authors:  L Steidler; W Hans; L Schotte; S Neirynck; F Obermeier; W Falk; W Fiers; E Remaut
Journal:  Science       Date:  2000-08-25       Impact factor: 47.728

5.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.

Authors:  S Schreiber; R N Fedorak; O H Nielsen; G Wild; C N Williams; S Nikolaus; M Jacyna; B A Lashner; A Gangl; P Rutgeerts; K Isaacs; S J van Deventer; J C Koningsberger; M Cohard; A LeBeaut; S B Hanauer
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

6.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.

Authors:  R N Fedorak; A Gangl; C O Elson; P Rutgeerts; S Schreiber; G Wild; S B Hanauer; A Kilian; M Cohard; A LeBeaut; B Feagan
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

Review 7.  Animal models of intestinal inflammation: ineffective communication between coalition members.

Authors:  Robin G Lorenz; Vance J McCracken; Charles O Elson
Journal:  Springer Semin Immunopathol       Date:  2005-07-19

8.  Modulation of human dendritic cell phenotype and function by probiotic bacteria.

Authors:  A L Hart; K Lammers; P Brigidi; B Vitali; F Rizzello; P Gionchetti; M Campieri; M A Kamm; S C Knight; A J Stagg
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

9.  Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells.

Authors:  Fang Yan; D Brent Polk
Journal:  J Biol Chem       Date:  2002-10-21       Impact factor: 5.157

10.  Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA.

Authors:  Denise Kelly; Jamie I Campbell; Timothy P King; George Grant; Emmelie A Jansson; Alistair G P Coutts; Sven Pettersson; Shaun Conway
Journal:  Nat Immunol       Date:  2003-12-21       Impact factor: 25.606
View more
  3 in total

Review 1.  Designer foods and their benefits: A review.

Authors:  A Rajasekaran; M Kalaivani
Journal:  J Food Sci Technol       Date:  2012-05-22       Impact factor: 2.701

2.  Probiotic therapy - recruiting old friends to fight new foes.

Authors:  Roy D Sleator
Journal:  Gut Pathog       Date:  2010-06-25       Impact factor: 4.181

Review 3.  Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation.

Authors:  Craig L Maynard; Casey T Weaver
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.